PharmacoEconomics Open (2017) 1:255–263 https://doi.org/10.1007/s41669-017-0018-3 ORIGINAL RESEARCH ARTICLE Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR) 1 2 3 1,4 • • • Lisa Masucci Jaclyn Beca Mona Sabharwal Jeffrey S. Hoch Published online: 22 March 2017 The Author(s) 2017. This article is an open access publication Abstract reviews with a ﬁnal funding recommendation (N = 34) Background Public drug plans are faced with increasingly were independently examined by two authors. Major difﬁcult funding decisions. In Canada, the pan-Canadian methodological issues from each review were abstracted Oncology Drug Review (pCODR) makes funding recom- and grouped into nine main categories. Each issue was also mendations to the provincial and territorial drug plans categorized based on perception of the reviewer’s actions responsible for cancer drugs. Assessments of the economic to manage it. models submitted by pharmaceutical manufacturers are Results The most commonly reported issues involved publicly reported. costing (59% of reviews), time horizon (56%), and model Objectives The main objective of this research was to structure (36%). Several types of issues were identiﬁed that identify recurring methodological issues in economic usually could not be resolved, such as quality of clinical models submitted to pCODR for funding
PharmacoEconomics - Open – Springer Journals
Published: Mar 22, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud